Is Tucatinib better than Neratinib in HER2-positive Breast Cancer?

2017 could well turn out to be a good year for HER2+ breast cancer with several new developments ongoing. We take a look...

January 30, 2017

Understanding the Mutational Landscape of Metastatic Breast Cancer

How crowdsourcing data from breast cancer patients may help future clinical R&D

January 24, 2017

Targeting Breast Cancer Stem Cells

Will cancer stem cell therapeutics impact the lives of people with metastatic breast cancer?

January 23, 2017

Challenges and Opportunities in Inflammatory Breast Cancer

SABCS16 expert interview on Inflammatory Breast Cancer with Dr Naoto Ueno from MD Anderson Cancer Center.

January 17, 2017

How circulating tumor DNA could change cancer treatment

SABCS16 expert interview on the potential of circulating tumor DNA to change the treatment of cancer.

January 16, 2017
Dr Leisha Emens SABCS16

Advances in Breast Cancer Immunotherapy

Second in our series of expert interviews from the 2016 San Antonio Breast Cancer Symposium features Dr Leisha Emens

January 13, 2017

Still looking for a JPM17 Licensing Deal? How about a First-in-Class Drug for Metastatic Breast Cancer?

First in a mini-series of expert interviews from the 2016 San Antonio Breast Symposium #SABCS16 with a leading researcher who has discovered a first-in-class compound with potential in metastatic breast cancer.

January 12, 2017
The Alamo, San Antonio TX

Emerging Trends from SABCS16 in San Antonio

3 trends from SABCS16 that you may hear more about

December 15, 2016